Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13116579 | 0.91 | HPGD (0.55) | KDM4EPOLBGAAALDH1A1ATM | |
| SCHEMBL8403022 | 0.88 | ALDH1A1 (0.67) | KDM4EPOLBGAAALDH1A1ATM | |
| SCHEMBL16132011 | 0.82 | ATM (0.58) | KDM4EPOLBGAAALDH1A1ATM | |
| SCHEMBL13778300 | 0.82 | KDM4E (0.56) | KDM4EPOLBGAAALDH1A1ATM | |
| SCHEMBL31313370 | 0.81 | NPC1 (0.67) | KDM4EPOLBALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL26426186 | 0.81 | NPC1 (0.67) | KDM4EPOLBALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL13280180 | 0.81 | HPGD (0.49) | KDM4EPOLBGAAALDH1A1ATM | |
| SCHEMBL13182960 | 0.79 | ALDH1A1 (0.59) | KDM4EPOLBGAAALDH1A1ATM | |
| SCHEMBL19645745 | 0.79 | MEN1 (0.58) | POLBALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL7652997 | 0.79 | KDM4E (0.59) | KDM4EPOLBGAAALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9844546-B2 | Antibody against human HIF hydroxylase | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-12-19 | — | — | US | disclosed |
| US-20170088876-A1 | Assays, Methods and Means | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-03-30 | — | — | US | disclosed |
| US-20160243099-A1 | ASSAYS, METHODS AND MEANS | ISIS INNOVATION LIMITED (GB) | 2016-08-25 | — | — | US | disclosed |
| US-20160101080-A1 | ASSAYS, METHODS AND MEANS | ISIS INNOVATION LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160101094-A1 | ASSAYS, METHODS AND MEANS | ISIS INNOVATION LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160097080-A1 | ASSAYS, METHODS AND MEANS | ISIS INNOVATION LIMITED (GB) | 2016-04-07 | — | — | US | disclosed |
| US-20160097076-A1 | ASSAYS, METHODS AND MEANS | ISIS INNOVATION LIMITED (GB) | 2016-04-07 | — | — | US | disclosed |
| US-20160097079-A1 | ASSAYS, METHODS AND MEANS | ISIS INNOVATION LIMITED (GB) | 2016-04-07 | — | — | US | disclosed |
| US-20160097078-A1 | ASSAYS, METHODS AND MEANS | ISIS INNOVATION LIMITED (GB) | 2016-04-07 | — | — | US | disclosed |
| US-20160097077-A1 | ASSAYS, METHODS AND MEANS | ISIS INNOVATION LIMITED (GB) | 2016-04-07 | — | — | US | disclosed |
| US-20150353646-A1 | ASSAYS, METHODS AND MEANS | ISIS INNOVATION LIMITED (GB) | 2015-12-10 | — | — | US | disclosed |
| US-20140294842-A1 | Assays, Methods and Means | ISIS INNOVATION LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294842-A1 | Assays, Methods and Means | EGLN3, EGLN2, P4HA1 | KDM4E 238/4885POLB 714/4885GAA 1245/4885 |
| US-20160097076-A1 | ASSAYS, METHODS AND MEANS | EGLN3, EGLN2, P4HA1 | KDM4E 239/4885POLB 699/4885GAA 1271/4885 |
| US-20160097079-A1 | ASSAYS, METHODS AND MEANS | EGLN3, EGLN2, P4HA1 | KDM4E 239/4885POLB 602/4885GAA 1381/4885 |
| US-20160101094-A1 | ASSAYS, METHODS AND MEANS | EGLN3, EGLN2, P4HA1 | KDM4E 239/4885POLB 602/4885GAA 1381/4885 |
| US-20160097078-A1 | ASSAYS, METHODS AND MEANS | EGLN3, EGLN2, P4HA1 | KDM4E 239/4885POLB 699/4885GAA 1271/4885 |
| US-20170088876-A1 | Assays, Methods and Means | EGLN3, EGLN2, P4HA1 | KDM4E 239/4885POLB 699/4885GAA 1271/4885 |
| US-20160243099-A1 | ASSAYS, METHODS AND MEANS | EGLN3, EGLN2, P4HA1 | KDM4E 239/4885POLB 699/4885GAA 1271/4885 |
| US-20150353646-A1 | ASSAYS, METHODS AND MEANS | EGLN3, EGLN2, P4HA1 | KDM4E 239/4885POLB 699/4885GAA 1271/4885 |
| US-20160101080-A1 | ASSAYS, METHODS AND MEANS | EGLN3, EGLN2, P4HA1 | KDM4E 239/4885POLB 602/4885GAA 1381/4885 |
| US-20160097077-A1 | ASSAYS, METHODS AND MEANS | EGLN3, EGLN2, P4HA1 | KDM4E 239/4885POLB 602/4885GAA 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.